Search Results

Aspen Neuroscience will present this week to a global audience of clinicians, regulators, researchers, technologists and industry partners at the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, May 29-June 1.

ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation at the 2024 American Society of Cancer Oncology Annual Meeting being held in Chicago from May 31-June 4, 2024.

ClearPoint Neuro, Inc. congratulates its partner Aspen Neuroscience, Inc. on use of the ClearPoint Neuro Navigation System to transplant dopaminergic neuron precursor cells for all enrolled patients with Parkinson’s Disease in its recently launched ASPIRO Phase 1/2a clinical trial.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced positive topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.

Aspen Neuroscience, Inc. has received a CLIN2 grant award of $8 million from the California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, to support clinical research aimed at treating Parkinson’s disease (PD).

Insmed Incorporated announced that it will host a conference call and webcast tomorrow, Tuesday, May 28, 2024, at 8:00 am ET to discuss topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.